PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

A Glaviano, ASC Foo, HY Lam, KCH Yap, W Jacot… - Molecular cancer, 2023 - Springer
Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

V Panwar, A Singh, M Bhatt, RK Tonk… - Signal transduction and …, 2023 - nature.com
The mammalian target of rapamycin (mTOR) is a protein kinase that controls cellular
metabolism, catabolism, immune responses, autophagy, survival, proliferation, and …

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival …

JR Strosberg, ME Caplin, PL Kunz… - The Lancet …, 2021 - thelancet.com
Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide …

Liver metastases

DI Tsilimigras, P Brodt, PA Clavien… - Nature reviews Disease …, 2021 - nature.com
Liver metastases are commonly detected in a range of malignancies including colorectal
cancer (CRC), pancreatic cancer, melanoma, lung cancer and breast cancer, although CRC …

Personalized management of pheochromocytoma and paraganglioma

S Nölting, N Bechmann, D Taieb… - Endocrine …, 2022 - academic.oup.com
Pheochromocytomas/paragangliomas are characterized by a unique molecular landscape
that allows their assignment to clusters based on underlying genetic alterations. With around …

[HTML][HTML] Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

M Pavel, K Öberg, M Falconi, EP Krenning, A Sundin… - Annals of …, 2020 - Elsevier
Neuroendocrine neoplasms (NENs) arise from the diffuse neuroendocrine cell system and
may occur at many different disease sites. Most frequently, these neoplasms occur in the …

Targeting the PI3K pathway in cancer: are we making headway?

F Janku, TA Yap, F Meric-Bernstam - Nature reviews Clinical oncology, 2018 - nature.com
Abstract The PI3K–AKT–mTOR pathway is one of the most frequently dysregulated
pathways in cancer and, consequently, more than 40 compounds that target key …

Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States

A Dasari, C Shen, D Halperin, B Zhao, S Zhou… - JAMA …, 2017 - jamanetwork.com
Importance The incidence and prevalence of neuroendocrine tumors (NETs) are thought to
be rising, but updated epidemiologic data are lacking. Objective To explore the evolving …

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

J Strosberg, G El-Haddad, E Wolin… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients with advanced midgut neuroendocrine tumors who have had disease
progression during first-line somatostatin analogue therapy have limited therapeutic options …

Gastroenteropancreatic neuroendocrine tumors

J Strosberg - The American Cancer Society's Oncology in …, 2018 - Wiley Online Library
Neuroendocrine tumors (NETs) are heterogeneous neoplasms that vary considerably based
on primary site, differentiation, and grade. A minority of NETs are characterized by the ability …